Trial Profile
A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms OTT10-06
- 01 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Mar 2012 New trial record